Genmab A/S

Equities

GMAB

DK0010272202

Biotechnology & Medical Research

Real-time Estimate Cboe Europe Other stock markets 14:32:19 16/07/2024 BST			5-day change	1st Jan Change
1,804 ^DKK	-0.25%		+2.18%	-16.38%

07-15	RBC Capital Upgrades Genmab to Outperform	MT
07-15	GENMAB : RBC raises its recommendation	CF

Genmab A/S Announces DARZALEX Sales Results for the Full Year 2023

January 23, 2024 at 11:24 am

Genmab A/S announced DARZALEX sales results for the full year 2023. For the year, the company reported worldwide net sales of DARZALEX (daratumumab) as reported by Johnson & Johnson were USD 9,744 million in 2023. Net trade sales were USD 5,277 million in the U.S. and USD 4,467 million in the rest of the world.

Latest news about Genmab A/S

RBC Capital Upgrades Genmab to Outperform	07-15	MT
GENMAB : RBC raises its recommendation	07-15	CF
RBC Upgrades Genmab to Outperform From Sector Perform, Keeps Price Target at DKK2,400	07-15	MT
Markets Powered by Alternating Current	07-10
Myricx Pharma Ltd announced that it has received £90 million in funding from a group of investors	07-07	CI
Myricx Bio announced that it has received £90 million in funding from a group of investors	07-07	CI
Would you like some more inflation?	06-28
Genmab, AbbVie's Lymphoma Therapy Recommended for Approval in EU	06-28	MT
AbbVie, Genmab Receive Positive European Opinion on Marketing Authorization for Possible Lymphoma Treatment	06-28	MT
Genmab A/S Announces Epcoritamab Receives Positive CHMP Opinion for Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma	06-28	CI
AbbVie Receives Positive CHMP Opinion for Epcoritamab for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma	06-28	CI
Genmab Closes DKK3.5 Billion Share Buyback Early	06-28	MT
BTIG Adjusts Price Target on Genmab to $47 From $46, Maintains Buy Rating	06-27	MT
Genmab Gets FDA Approval for Follicular Lymphoma Treatment	06-27	MT
Genmab Wins US Approval for Follicular Lymphoma Treatment	06-27	MT
Genmab A/S Announces That the U.S. Food and Drug Administration Approved Epkinly® (Epcoritamab-Bysp) for the Treatment of Adults with Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic EPKINLY	06-27	CI
U.S. Food and Drug Administration Grants Second Approval for AbbVie's EPKINLY (epcoritamab-bysp) to Treat Patients with Relapsed or Refractory Follicular Lymphoma	06-27	CI
AbbVie Gets New FDA Accelerated Approval for Epkinly	06-26	DJ
Transcript : Genmab A/S Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 09:20 AM	06-10
Truist Securities Raises Price Target on Genmab to $53 From $50, Maintains Buy Rating	06-04	MT
Genmab's Tisotumab Shows 'Encouraging' Antitumor Activity in Phase 2 Head, Neck Cancer Study	06-03	MT
Transcript : Genmab A/S - Special Call	06-03
Genmab A/S Announces Data from the Phase 2 Innovatv 207 Trial, Investigating Tisotumab Vedotin	06-03	CI
Genmab A S and BioNTech SE Announces Initial Data from the Ongoing Phase 2 Trial	06-03	CI
Genmab Announces Initial Data from Phase 2 Cancer Treatment Trial	06-03	MT

Chart Genmab A/S

Duration

Period

More charts

Company Profile

Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (83.2%); - income from research and development (12.4%); - other (4.4%): primarily income from partnership agreement. At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase. Denmark accounts for all net sales.

Sector

Biotechnology & Medical Research

Calendar

01/08/2024 - Q2 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

GENMAB : A good start to 2024; guidance unchanged

May 03, 2024 at 06:08 pm

More Strategies

Ratings for Genmab A/S

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1,809 DKK

Average target price

2,446 DKK

Spread / Average Target

+35.23%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
GENMAB A/S	-16.38%	16.79B
VERTEX PHARMACEUTICALS INCORPORATED	+20.63%	127B
REGENERON PHARMACEUTICALS, INC.	+23.21%	117B
ARGENX SE	+25.18%	27.67B
BIONTECH SE	-20.17%	20.33B
BEIGENE, LTD.	-18.07%	15.63B
NEUROCRINE BIOSCIENCES, INC.	+11.92%	14.84B
WUXI APPTEC CO., LTD.	-47.70%	14.65B
SAREPTA THERAPEUTICS, INC.	+58.32%	14.43B
INSMED INCORPORATED	+149.98%	12.49B

Bio Therapeutic Drugs